Dr Vivek Kumar
Senior Research Fellow
Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organisation (DRDO)
(2021 - 2024)
Delhi
Expertise:
Pharmacology and Pharmacy
10
Publications
4
Projects
24
Scopus Citations
64
CrossRef
5 Years 6 Months Total Experience
Scopus
24
Citations
3
h-index
CrossRef
64
Citations
5
h-index
Google Scholar
Loading Scholar statistics...
Professional Recognition
Merit in M.Pharm
2016
Institute of pharmaceutical Sciences, GLA University, Mathura, U. P
Merit in B.Pharm
2018
Institute of pharmaceutical Sciences, GLA University, Mathura, U. P
Technology Award
2021
Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organisation (DR
Best Oral Presentation
2021
Assopharm, Pharma Summit: Drug Discovery & Community Trial
Best Oral Presentation
2021
Institute of pharmaceutical Sciences, GLA University, Mathura, U. P
Community & Membership
No Data Found
There is currently nothing to display here.
Registered Pharmacist
State Pharmacy CouncilPersonal Details
Doctor of Philosophy
2025
N/A
Master of Arts
2018
N/A
Bachelor of Pharmacy
2016
N/A
Senior Research Fellow
Mar 2021 – Mar 2024
Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organisation (DRDO)
Junior Research Fellow
Mar 2019 – Mar 2021
Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organisation (DRDO)
Project Assistant
Oct 2018 – Feb 2019
Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organisation (DRDO)
Medical and Health Sciences
Scholarly Work
Internal Decorporation of Radio nuclides: Development of Formulation and Therapeutic Strategies
CompletedTDF Project: Development of Prussian Blue formulations under GMP facility for nuclear warfare: under Technology Development Fund
CompletedTask Project: Development of pharmaceutical dosage form of Prussian blue with pH modifying agents having improved decorporation efficacy
CompletedEvaluation of Pharmacological Significance of Cyclooxygenase-2 Inhibitors in the management of obsessive-compulsive disorder
CompletedNo Data Found
There is currently nothing to display here.
Pharmaceutical Composition Comprising of Prussian blue Insoluble and thereof
INMAS
DRDO
-
Application No. :
202311054548
Filed :
01-12-2023
Published :
30-11--0001
Published
Scholarly Publications
Celecoxib potentiates the anti-obsessive compulsive disorder-like activity of fluoxetine in experimental animal..
In vitro and in vivo removal efficacy of insoluble Prussian blue in combination with calcium polystyrene sulfonate for thallium
A review on artificial intelligence in pharmaceutical sciences: opportunities and challenges
10.1080/03639045.2026.2670435
Scopus: 1
Toxicity and antidotal treatment by synthesized and optimized ferric(III) hexacyanoferrate(II) for thallium
Open Access
10.1186/s42269-023-01086-x
Crossref: 6
Homocysteine, Vitamin B12 and Folate Level: Possible Risk Factors in the Progression of Chronic Heart and Kidney Disorders
10.2174/1573403x19666230209111854
Crossref: 25
Physicochemical Characterisation of Commercially Available Prussian Blue Insoluble Samples and Its Comparison with Radiogardase Cs
Open Access
10.14429/dlsj.8.18464
Crossref: 4
Oral formulation of Prussian blue with improved efficacy for prophylactic use against thallium
10.1080/03639045.2023.2189958
Crossref: 8
Quantitative evaluation of Chlorella vulgaris for removal of toxic metals from body
Showing 1 to 8 of 10 publications